Bachleda Mark has filed 3 insider transactions across 2 companies since February 2023.
Most recent transaction: a grant/award of 13000 shares of Lyell Immunopharma, Inc. ($LYEL) on June 09, 2025.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 9, 2025 | Lyell Immunopharma, Inc. | $LYEL | Bachleda Mark | Not found | A | Option (right to buy) | 13000 | $0.00 | 13,000.0000 | 295,228,868 | 9999.99% | 0.00% |
| March 16, 2023 | Galera Therapeutics, Inc. | $GRTX | Bachleda Mark | Chief Commercial Officer | P | Common Stock | 11000 | $2.25 | 11,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 25, 2023 | Galera Therapeutics, Inc. | $GRTX | Bachleda Mark | Chief Commercial Officer | A | Stock Option (Right to Buy) | 135000 | $0.00 | 135,000.0000 | 0 | 9999.99% | 0.00% |